Clinical Application of the Heart Rate Deceleration Capacity Test to Predict Epirubicin-induced Cardiotoxicity

about

Clinical Application of the Heart Rate Deceleration Capacity Test to Predict Epirubicin-induced Cardiotoxicity

Item

http://www.wikidata.org/entity/Q36136774

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical Application of the He ...... rubicin-induced Cardiotoxicity

@ast

Clinical Application of the He ...... rubicin-induced Cardiotoxicity

@en

type

Item

label

Clinical Application of the He ...... rubicin-induced Cardiotoxicity

@ast

Clinical Application of the He ...... rubicin-induced Cardiotoxicity

@en

prefLabel

Clinical Application of the He ...... rubicin-induced Cardiotoxicity

@ast

Clinical Application of the He ...... rubicin-induced Cardiotoxicity

@en

P1476

Clinical Application of the He ...... rubicin-induced Cardiotoxicity

@en

P2093

Yan-ying Feng

http://www.w3.org/2001/XMLSchema#string

Zhi-jun Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Cholinergic activity as a new target in diseases of the heart

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

Approaches to sudden death from coronary heart disease.

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.

Reflex and tonic autonomic markers for risk stratification in patients with type 2 diabetes surviving acute myocardial infarction.

Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy.

Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study.

Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure.

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.

P304

371-375

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FJC.0000000000000289

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278786930

http://www.w3.org/2001/XMLSchema#string

P698

26080056

http://www.w3.org/2001/XMLSchema#string

P932

4598070

http://www.w3.org/2001/XMLSchema#string